Discrepancies Emerge in NHS Palantir Federated Data Platform Benefit Reporting
Campaigners challenge government claims as trusts deny using the controversial data platform.
1Data Discrepancy Claims
Medact reports that 29 NHS trusts listed as benefiting from Palantir's Federated Data Platform deny using the system. This figure represents 21 percent of the 137 trusts NHS England claims are currently realizing benefits. These findings emerge as the government prepares to decide on the future of the £330 million contract.
2Trusts Deny Implementation
University Hospitals of North Midlands NHS Trust explicitly stated in a July Freedom of Information response that the platform is not live. They confirmed no future rollout plans exist, citing a lack of functionality beyond existing tools. Similarly, Nottingham University Hospitals reported that no implementation timeline has been agreed upon for the software.
3Government Contract Timeline
The UK government faces a critical December deadline to determine if the £330 million agreement with the Palantir-led consortium should continue. This follows an initial £60 million pandemic-era contract awarded without competition. The current FDP contract, awarded in November 2023, aims to integrate operational data across separate systems to improve staff efficiency.
4Palantir Performance Metrics
Palantir claims its software facilitates 100,000 additional operations and a 12 percent reduction in discharge delays. The company also reports the removal of 675,000 patients from waiting lists through its tools. However, these figures remain under intense scrutiny following a directive from the UK statistical regulator regarding the accuracy of reported benefits.
5Regulatory Oversight Challenges
The UK statistical regulator previously instructed NHS England to ensure greater accuracy when quoting performance figures. This intervention followed public disputes regarding data used to promote the platform's purported advantages. The ongoing tension highlights the difficulty in verifying operational improvements attributed to the platform across diverse and independent NHS trust environments.
6Parliamentary Exit Strategy
Dame Chi Onwurah, chair of the Science and Technology Committee, has demanded clarification regarding potential exit plans. Junior minister James Frith confirmed that exit measures exist but refused to publish details, citing commercial interests. The government maintains that intellectual property rights for NHS-built components are protected, ensuring a transition path if necessary.
7NHS England Official Stance
NHS England maintains that the platform is universally available, allowing local organizations to select tools based on specific needs. They insist that 137 trusts have reported benefits from the wide range of available tools. The organization continues to defend the platform's role in joining up patient care and improving overall operational efficiency.
8Future Contractual Implications
The outcome of the December decision will determine the long-term integration of Palantir within the NHS infrastructure. With 21 percent of trusts disputing their status, the government faces pressure to provide transparent evidence. The final decision will balance the need for digital transformation against concerns regarding vendor reliance and data reporting accuracy.